Pfizer Inc. (PFE)

Pfizer's stock has been influenced by several key events in the past six months. A Q4 2025 earnings report surpassed forecasts, leading to a stock gain, but earlier in February 2026, the stock declined due to investor concerns about future growth and declining COVID-related revenues. Positive catalysts include encouraging GLP-1 obesity data, pipeline activity in obesity and oncology, and the FDA granting priority review for Hympavzi. Pfizer reported solid full-year 2025 results and reaffirmed its full-year 2026 financial guidance.

Pfizer's stock has historically exhibited some seasonal patterns. Over the past 20 years, a "Buy Date" of July 9 and a "Sell Date" of October 3 has resulted in an average return above the S&P 500. February has shown a historical tendency to be a "green month". Demand for certain Pfizer products, particularly COVID-19 related offerings, has shown fluctuations tied to infection rates and vaccine recommendations.

Pfizer Inc., founded in 1849 and headquartered in New York City, is a multinational biopharmaceutical corporation operating in the Pharmaceutical and Biotechnology sectors. It develops and produces medications and vaccines across various therapeutic areas, including immunology, oncology, and cardiology. Major products in 2024 included Eliquis, Prevnar, Paxlovid, Vyndaqel, Comirnaty, and Ibrance, among others.

Pfizer has a significant global presence, selling its products in over 125 markets and approximately 200 countries and territories. In 2024, the United States accounted for 61% of revenues, China for 4%, and other countries for 35%. The international division, including emerging markets and China, showed operational growth in Q2 2025. The company operates 39 manufacturing sites globally.

Pfizer's brand reputation has been shaped by its role in biopharmaceutical innovation. The company experienced a significant improvement in its reputation during the COVID-19 pandemic due to its vaccine development efforts, leading to a more favorable media perception. Pfizer launched a corporate campaign and underwent a brand refresh to underscore its identity as a science-driven company. However, Pfizer faces scrutiny related to regulatory and market pressures, intellectual property, and cybersecurity risks.

Pfizer Inc. has a substantial number of institutional owners and shareholders. As of February 5, 2026, 3632 institutions held a total of 4,013,598,339 shares. Major institutional shareholders include Vanguard Group Inc, BlackRock, Inc., and State Street Corp. Top individual/insider shareholders include Albert Bourla, Mikael Dolsten, and Douglas Lankler.